Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Postpones Annual General Meeting
DGAP-News: Vivoryon Therapeutics AG
/ Key word(s): AGM/EGM
Vivoryon Therapeutics AG Postpones Annual General Meeting
HALLE (SAALE) / Munich, Germany, 12 May 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which was previously scheduled for June 24, 2020 in Halle (Saale). The decision was made by the Company's management team with subsequent approval from the Supervisory Board. ###
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.
12.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Vivoryon Therapeutics AG |
Weinbergweg 22 | |
06120 Halle/Saale | |
Germany | |
Phone: | +49 (0)345 555 9900 |
Fax: | +49 (0)345 555 9901 |
E-mail: | contact@vivoryon.com |
Internet: | www.vivoryon.com |
ISIN: | DE0007921835 |
WKN: | 792183 |
Listed: | Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam |
EQS News ID: | 1040825 |
End of News | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: